Felodipine
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
- Felodipine
- Felodipine: From Hypertension/Angina to Prinzmetal Angina (Lead Candidate Among 7 TxGNN Predictions)
Felodipine: From Hypertension/Angina to Prinzmetal Angina (Lead Candidate Among 7 TxGNN Predictions)
One-Sentence Summary
Felodipine is a dihydropyridine calcium-channel blocker (calcium antagonist) with vascular selectivity, referenced in the evidence base for its use in hypertension, angina, and heart failure hemodynamics. The TxGNN model generated 7 candidate new indications for this drug (candidate pack TW-DB01023-multi); the most credible finding is Prinzmetal (variant) angina, supported by 3 RCTs and 6 additional publications, while the remaining 6 candidates range from moderate mechanistic plausibility to likely knowledge-graph noise with no supporting evidence.
Quick Overview (Lead Candidate: Prinzmetal Angina)
| Item | Content |
|---|---|
| Original Indication | Not stated in structured regulatory data (original_indications empty; MOA marked as data gap DG002). Cardiovascular/antihypertensive use is inferable only from the cited literature (calcium antagonist). |
| Predicted New Indication | Prinzmetal Angina |
| TxGNN Prediction Score | 99.07% (rank 7,125) |
| Evidence Level | L2 (1 completed RCT class evidence; 3 RCTs total identified) |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Note: This evidence pack contains 7 ranked candidate indications for felodipine, not one. A full breakdown of all 7 is provided below because TxGNN score alone (rank 1–5 all score >99.8%) does not track with actual evidence quality — the highest-scoring candidates (rank 1–3, 5) have zero supporting trials or literature.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 1 | Pulmonary hypertension, unclear multifactorial mechanism | 99.91% | L5 | S0 | Hold |
| 2 | Pulmonary hypertension owing to lung disease/hypoxia | 99.91% | L5 | S0 | Hold |
| 3 | Malignant hypertensive renal disease | 99.90% | L5 | S0 | Hold |
| 4 | Malignant renovascular hypertension | 99.90% | L4 | S0 | Hold |
| 5 | Braddock syndrome | 99.88% | L5 | S0 | Hold |
| 6 | Chronic pulmonary heart disease (cor pulmonale) | 99.19% | L3 | S2 | Research Question |
| 7 | Prinzmetal angina | 99.07% | L2 | S3 | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data (original_moa) is flagged as a data gap (DG002) and could not be retrieved from DrugBank in this pull. However, the literature captured in this evidence pack consistently describes felodipine as a dihydropyridine calcium-channel blocker with vascular selectivity, acting by blocking L-type calcium channels in vascular smooth muscle (see PMIDs 2487551, 2838319, 3154329, 7728649).
For Prinzmetal (variant) angina, the pathophysiology is coronary artery vasospasm — a mechanism directly addressed by dihydropyridine CCBs, which are already standard first-line therapy for this condition. Felodipine specifically has direct RCT evidence preventing ergonovine-induced and hyperventilation-induced coronary spasm, and head-to-head non-inferiority against nifedipine (the established comparator in this indication). This is the strongest mechanistic and clinical link among the 7 candidates.
For chronic pulmonary heart disease (rank 6), felodipine's systemic and pulmonary vasodilation reduced pulmonary vascular resistance and increased cardiac output in small 1980s hemodynamic studies of COPD and severe CHF patients — a plausible but dated and non-outcome-based signal.
For the four weakest candidates (ranks 1, 2, 3, 5), the TxGNN scores are similarly high (>99.8%) but the underlying evidence is either absent or off-target: rank 2's 20 retrieved PubMed articles are generic hypoxia-biology papers (brain aging, cancer metabolism) with no direct link to felodipine or pulmonary hypertension, and rank 5 (Braddock/CHOPS syndrome, a COG1-related congenital disorder) has no plausible calcium-channel pathophysiology at all. These are most consistent with knowledge-graph false positives rather than genuine repurposing signals.
Clinical Trial Evidence
No registered clinical trials (ClinicalTrials.gov or ICTRP) were found for felodipine in any of the 7 predicted indications.
Currently no related clinical trials registered for felodipine in these predicted indications.
Literature Evidence
Lead Candidate — Prinzmetal Angina (L2, 9 publications)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8013514 | 1994 | RCT | European Heart Journal | Once-daily felodipine ER prevented ergonovine-induced myocardial ischemia in 14 Prinzmetal angina patients |
| 1746458 | 1991 | RCT | American Journal of Cardiology | Once-daily felodipine matched four-times-daily nifedipine in controlling Prinzmetal angina in 30 patients |
| 7744087 | 1995 | RCT | European Heart Journal | Double-blind crossover vs nifedipine SR and placebo; felodipine ER improved exercise duration by 66s in exercise-induced angina |
| 14689111 | 2003 | Review | Herz | Reviews differential efficacy of calcium antagonists across hypertension and angina subtypes |
| 7728649 | 1995 | Review | Canadian Journal of Cardiology | CCBs are first-choice therapy in Prinzmetal angina via antivasospastic action; felodipine discussed specifically |
| 3345765 | 1988 | Cohort | European Heart Journal | Case series documenting exercise-induced ST elevation consistent with coronary spasm mechanism |
| 2909138 | 1989 | Cohort/small clinical study | American Journal of Cardiology | Felodipine reduced hyperventilation-induced ischemic attacks in variant angina |
| 15222138 | 2004 | Case report | Orvosi Hetilap | Nicergoline-induced Prinzmetal angina case (background pathophysiology, not felodipine-specific) |
| 19052677 | 2008 | Case report | Canadian Journal of Cardiology | Vasospasm-induced polymorphic ventricular tachycardia case (background, not felodipine-specific) |
Secondary Candidate — Chronic Pulmonary Heart Disease (L3, 3 publications)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 2487551 | 1989 | Open-label hemodynamic study | Cardiovascular Drugs and Therapy | Acute felodipine infusion assessed in severe chronic congestive heart failure; regional blood flow effects measured |
| 2838319 | 1988 | Open-label hemodynamic study | European Respiratory Journal | Felodipine infusion reduced pulmonary vascular resistance 18% and systemic vascular resistance 33%, increased cardiac output 33% in severe COPD |
| 3154329 | 1988 | Review | Cardiovascular Drugs and Therapy | Reviews calcium antagonists' minor/secondary indications in hypertension and arrhythmias |
Weak/Unsupported Candidates — Not Tabulated
- Malignant renovascular hypertension (rank 4, L4): only 1 retrieved publication (8893190, 1996 case report) — describes renovascular hypertension after adrenalectomy, not a felodipine efficacy study.
- Pulmonary hypertension owing to lung disease/hypoxia (rank 2, L5): 20 publications retrieved, but all are generic hypoxia-biology papers (brain aging, cancer metabolism, altitude physiology) with no direct relevance to felodipine or this indication — treated as evidentiary noise.
- Pulmonary hypertension, unclear multifactorial mechanism (rank 1, L5) and malignant hypertensive renal disease (rank 3, L5): no clinical trials or literature retrieved.
- Braddock syndrome (rank 5, L5): no clinical trials or literature retrieved; no known pathophysiological link to calcium-channel modulation. Flagged as a likely false-positive association and recommended for exclusion from further follow-up.
New Zealand Market Information
Felodipine currently holds 0 authorizations and is not marketed in New Zealand under this evidence pack. No product license records are available to summarize.
Safety Considerations
Please refer to the package insert for safety information. Structured safety data (key warnings, contraindications, drug-drug interactions) could not be retrieved for this evidence pack — the TFDA/regulatory package insert query is flagged as a Blocking data gap (DG001), and the DDI database query returned no results.
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Prinzmetal angina, the lead candidate) — Hold for the remaining 6 candidates.
Rationale:
- Prinzmetal angina has direct RCT-level evidence (3 trials) and a well-established mechanistic basis (CCBs are already standard therapy for coronary vasospasm), supporting cautious advancement (L2/S3).
- Chronic pulmonary heart disease has plausible but dated (1980s), non-outcome hemodynamic evidence only (L3/S2) — warrants a research question rather than action.
- The four remaining candidates (pulmonary hypertension ×2, malignant hypertensive/renovascular hypertension, Braddock syndrome) have no or off-target evidence (L4–L5) and should remain on Hold; Braddock syndrome in particular should be deprioritized as a probable knowledge-graph false positive.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain the TFDA/manufacturer package insert to complete the S1 safety screen — this is currently blocking any indication from advancing past S0/S1.
- Resolve DG002 (High): confirm felodipine's formal mechanism of action via DrugBank API rather than relying on literature-inferred descriptions.
- For Prinzmetal angina: update the evidence base with contemporary (post-1995) trials or guideline citations, since all 3 RCTs are from 1991–1995; confirm current DDI profile before any clinical use.
- Since felodipine is not currently marketed in New Zealand (0 licenses), a regulatory pathway/market-entry assessment would be required before any repurposing indication could be operationalized locally.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.